Breast cancer (invasive) · line 1 · THP — docetaxel + trastuzumab + pertuzumab (HER2+ metastatic 1L)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy	1
Track	standard
Linked regimen	`REG-THP-METASTATIC`

ID	`IND-BREAST-HER2-POS-MET-1L-THP`
Type	Indication
Status	pending_clinical_signoff
Diseases	`DIS-BREAST`
Sources	`SRC-ESMO-BREAST-METASTATIC-2024` `SRC-NCCN-BREAST-2025`

Notes

CLEOPATRA standard. After T-DXd availability the question of THP-vs- T-DXd 1L is being studied (DESTINY-Breast09); current standard remains THP for 1L unless visceral crisis or rapid progression where T-DXd considered.

Used By

Algorithms

ALGO-BREAST-1L - ALGO-BREAST-1L

Handbook Chapters

HB-BREAST-HER2-POS-MET-1L - HER2+ metastatic breast cancer: first-line reasoning

Handbook Questions

HQ-BREAST-HER2-POS-1L-001 - HQ-BREAST-HER2-POS-1L-001

Red flag

RF-BREAST-EARLY-STAGE - Early-stage (non-metastatic) breast cancer: clinical or pathological stage I, II, or III....